Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans

Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.

Sorensen said Hemab is pursuing a strategy to build “a multiple product, exclusive coagulation franchise company” focused on blood coagulation disorders. The company’s lead program, sutacimig, has completed a Phase I/II study in Glanzmann’s thrombasthenia and is expected to enter a pivotal Phase III trial in the second half of this year, he said.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.